Loading clinical trials...

An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors | Clinical Trials | Clareo Health

RECRUITINGNA

An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors

A Prospective Trial to Evaluate Immune Determinants of the Response and the Toxicity to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors

NCT05481502•Gustave Roussy, Cancer Campus, Grand Paris

View on ClinicalTrials.gov

Summary

This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs. The second objective is to explore phenotypic and transcriptional changes of different cellular components in blood and bone marrow following injection of somatic cell therapy drugs.Then correlate the phenotypic and transcriptional profile of different tumor, blood and bone marrow immune populations with clinical response and/or toxicity. And to finish this study is designed in order to identify a phenotypic, transcriptional and epigenetic profile of intra-tumoral adoptive cells and correlate this profile with clinical response and/or toxicity.

Eligibility

Age

2 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient affiliated to a social security regimen
•Tumor lesion accessible to core biopsies
•Patient who is fully informed, able to comply with the protocol and who signed the informed consent
•Pediatric patients \> than 2 years old can be included
•No restriction about the Eastern Cooperative Oncology Group (ECOG) status

Exclusion Criteria

•Coagulation abnormality prohibiting a biopsy (but patients can still give their consent for blood and bone marrow samples).
•Tumor lesion not accessible to core biopsies.
•Pregnant or nursing women cannot participate in this study.

Locations (1)

Gustave Roussy Cancer Campus Grand Paris

Villejuif, Val De Marne, France

Key Dates

Start Date

June 8, 2022

Primary Completion Date

July 1, 2027

Completion Date

July 1, 2027

Last Updated

June 24, 2025

Enrollment

160

ESTIMATED participants

Conditions

Solid Tumor, AdultSolid Tumor, ChildhoodHematologic Cancer

Interventions

Tumor biopsy

PROCEDURE

Blood sample

PROCEDURE

Bone marrow sample

PROCEDURE

Contacts

Camille BIGENWALD, MD

CONTACT

+33 (0)1 42 11 42 29 camille.bigenwald@gustaveroussy.fr

Cristina CASTILLA LLORENTE, MD

CONTACT

+33 (0)1 42 11 42 39 cristina.castilla-llorente@gustaveroussy.fr

Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy

NCT05223608

Solid Tumor, Adult

View study

RECRUITINGPHASE1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775

Solid Tumor, AdultMetastatic Breast Cancer+9 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors

Inclusion Criteria

Exclusion Criteria

Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

COAST Therapy in Advanced Solid Tumors and Prostate Cancer